Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 128,578

Document Document Title
WO/2017/181849A1
The present invention relates to an indoleamine 2,3-dioxygenase inhibitor having the structure of formula (I), a preparation method therefor, and an application. The IDO inhibitor is an N'-hydroxyl-N-phenylformamidine derivative, has hig...  
WO/2017/185027A1
Disclosed are methods and compositions for treating a subject having a neurological disorder such as major depressive disorder (MDD). The methods and compositions may be utilized in order to inhibit trafficking of hyperpolarization-activ...  
WO/2017/181898A1
Provided are nine multi-target polypeptides of an opioid and a neuropeptide FF receptor, where an amino acid is replaced on the basis of opioid peptide biphalin- and NPFF-based chimeric peptide BN-9, and acquired are the multi-target pol...  
WO/2017/184658A1
The present disclosure relates to compounds of formula I which inhibit NaV1.7, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.  
WO/2017/178510A1
The present invention relates to arylamide derivatives having dual pharmacological activity towards both the α2δ subunit, in particular the α2δ-1 subunit,of the voltage-gated calcium channel and the µ-opioid receptor, to processes o...  
WO/2017/178344A1
This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar1 ...  
WO/2017/179225A1
Provided is a composition which can effectively suppress or improve physical hypofunction observed with age or physical dysfunction occurring with age, or mental hypofunction observed with age or mental dysfunction occurring with age, sa...  
WO/2017/179354A1
The purpose of the present invention is to provide a composition that is effective for maintaining, enhancing and improving recognition functions, etc. According to the present invention, a composition for maintaining, enhancing and/or i...  
WO/2017/178663A1
The present invention relates to Orally Inhaled and Nasal Drug Product (OINDP) comprising a benzodiazepine, in particular remimazolam.  
WO/2017/178807A1
The present invention relates to the use of cannabidivarin (CBDV) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). In a furth...  
WO/2017/181004A1
The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a ph...  
WO/2017/178339A1
This invention relates to compounds of formula (I) a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R...  
WO/2017/178499A1
The present invention relates to inhibitors of glucosylceramide degradation, to pharmaceutical compositions containing same and to the use of same in the treatment of diseases of the motor units, such as amyotrophic lateral sclerosis.  
WO/2017/180589A1
The present disclosure provides compounds of Formula I and/or Formula II, or pharmaceutically acceptable salts thereof: wherein D is deuterium and each deuterium has deuterium enrichment of no less than about 10%, compositions containing...  
WO/2017/180025A3
The invention relates to the field of pharmacology and may be used for the prevention and treatment of diseases related to the occurrence of glutamate stress. The aim of the present invention consists in creating an accessible neuroprote...  
WO/2017/178511A1
The invention relates to a cell population comprising a hematopoietic stem cell (HSC) and a hematopoietic progenitor cell (HPC), for use in the treatment of Parkinsonism in a subject, and to pharmaceutical compositions and kits for use i...  
WO/2017/179646A1
A cell secreted-type amylospheroid (ASPD)-like structure, a drug and vaccine using the same, and a production method thereof are provided. This production method involves a step in which cells expressing amyloid precursor protein (APP), ...  
WO/2017/180781A1
Disclosed are methods and compositions for the treatment of autism spectrum disorder, related disorders and symptoms of such disorders, comprising co-administration of an oxytocin peptide and magnesium ions. Co-administration of an oxyto...  
WO/2017/180064A1
The invention relates to medicine and veterinary applications, in particular, as a means for effective control of acute and/or chronic pain, and may be used in emergency medicine for the treatment of acute and/or chronic pain, including ...  
WO/2017/177261A1
Pharmaceutical preparations comprising cannabinoid resins encapsulated in liposomes are provided. The preparations are characterised by particular molar ratios of carboxyl containing cannabinoids to their decarboxylated counterparts. Als...  
WO/2017/177999A1
According to the invention, melatonin or melatonergic substances are used for treating an REM sleep behaviour disorder in a human. According to the invention, an unspecified dose of melatonin is taken in a previously specified time windo...  
WO/2017/178340A1
This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, ...  
WO/2017/177838A1
The present invention relates to substituted 2,4-(1H, 3H)-pyrimidinedione derivatives and the use thereof as therapeutically effective poly(ADP-ribose)polymerase (PARP) inhibitors. In particular, the present invention relates to the use ...  
WO/2017/178341A1
The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyrazinylamino)-propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, p...  
WO/2017/179602A1
The present invention addresses the problem of providing a brain function-improving composition for newborns, particularly newborns who are just after birth. According to the present invention, a brain function-improving agent for newbor...  
WO/2017/177896A1
Disclosed in the present invention are a compound represented by formula (I), a geometric or optical isomer, a pharmaceutically acceptable salt, a solvate or a polymorph thereof. Also disclosed in the present invention is a composition o...  
WO/2017/179647A1
A peptide is provided which has a binding inhibitory function that inhibits binding between amylospheroids (ASPD) and neurons. The polypeptide, represented by expression (I) or (II), is synthesized, isolated or purified. X1X2X3X4 (I) In ...  
WO/2017/179707A1
The present invention provides a novel combination for improving frailty or a novel combination for suppressing reduction in skeletal muscle mass. More specifically, the present invention provides a combination for improving frailty or a...  
WO/2017/179644A1
Disclosed are: a cognitive function-remedying agent which contains, as active ingredients, vitamin A, vitamin B compounds (B1, B2, B6 and B12), vitamin C, vitamin D, vitamin E, zinc, magnesium, pantothenic acid, biotin and folic acid; an...  
WO/2017/178338A1
This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, ...  
WO/2017/178810A1
The present invention relates to the use of cannabidiolic acid (CBDA) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders, such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). CBDA ...  
WO/2017/178515A1
The present invention relates to piperidinylalkylamide derivatives having dual pharmacological activity towards both the sigma (σ) receptor and the μ-opioid receptor, to processes of preparation of such compounds, to pharmaceutical com...  
WO/2017/178343A1
The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyridinylamino)propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, pa...  
WO/2017/178456A1
The invention relates to a carotenoid for use in the treatment or prevention of stress induced conditions, and in particular it relates to the treatment or prevention of a disease mediated by glucocorticoid receptor activity. The inventi...  
WO/2017/178685A1
The invention relates to the use of a composition comprising an aminosalicylate in the production of a drug for the relief, improvement, prevention and/or treatment of diseases or disorders related to an aggregating protein, specifically...  
WO/2017/177148A1
Death receptor 5 (DR5) agonist compositions and methods for treating pancreatitis have been developed. The compositions include Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL), its analogues, and anti-DR5 agonistic antibo...  
WO/2017/176619A1
This document provides materials and methods for treating a damaged optic nerve in a mammal to restore visual function comprising administering a population of induced pluripotent stem cell-derived oligodendrocyte precursor cells. This d...  
WO/2017/176109A1
The invention pertains to the use of therapeutically effective amounts of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof, (ii) docosahexaenoic acid (22:6; DHA), and/or eicosapentaenoic a...  
WO/2017/173800A1
The present invention provides an application using an MAPK signal pathway inhibitor for preparing a pharmaceutical product for delaying dopaminergic neuron degeneration, and specifically provides an application in preparing a pharmaceut...  
WO/2017/174999A1
There are described novel compounds of formula I: in which R1, R2, R3, R4, R5, X1 and X2 are each as herein defined, for use in the treatment or alleviation of an RAR mediated condition: and methods related thereto.  
WO/2017/177240A1
The present invention provides a plant-based medicament for treatment for opiate addiction having reduction ability on addiction liability of opiate narcotics. The medicament according to the invention is safe, non-addictive, has reducti...  
WO/2017/173604A1
Provided herein are compounds of the formula (I) : as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containin...  
WO/2017/173973A1
The present disclosure provides a nitrogen heterocyclic tryptamine ketone derivative and application thereof as an indoleamine 2,3-dioxygenase 1 (IDO1) and/or tryptophan 2,3-dioxygenase (TDO) inhibitor. The derivative is represented by f...  
WO/2017/175457A1
Provided is a therapeutic/prophylactic agent for Alzheimer disease, which uses a safe food-derived compound and which has an excellent therapeutic/preventive effect. This therapeutic/prophylactic agent for Alzheimer disease is formed by ...  
WO/2017/177160A1
Formulations, methods of manufacturing, methods of stabilizing, kits, and uses as medicament are provided, for example for the treatment of pain. The formulations can comprise gabapentin optionally combined with at least one non-opioid p...  
WO/2017/174847A1
The invention relates to a nanoparticle comprising: (i) between 60 wt.-% and 99 wt.-% sorbitan ester, relative to the total weight of the nanoparticle; (ii) a positively charged substance; and (iii) an miRNA. The invention also relates t...  
WO/2017/176108A1
The invention pertains to the use of therapeutically effective amounts of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof, (ii) docosahexaenoic acid (22:6; DHA), and/or eicosapentaenoic a...  
WO/2017/176385A1
Provided herein are compositions, devices, kits and methods for the diagnosis and treatment of brain injury. Certain agents herein detect, inhibit, suppress, abrogate or modulate acute or chronic immune response associated with brain inj...  
WO/2017/176962A1
The invention provides substituted pyrrolo[1,2-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorder...  
WO/2017/176961A1
The invention provides substituted imidazo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorder...  

Matches 551 - 600 out of 128,578